drugset
Drugs / mRNA COVID-19 Vaccine
last change Nov 2025 re-read 3 minutes ago

mRNA COVID-19 Vaccine

Messenger RNA (mRNA)

Developed for
COVID-19 · influenza
Investigated by
Duke University · Centers for Disease Control and Prevention · Arizona State University · Children's Hospital Medical Center, Cincinnati · Cleveland VA Medical Center · Columbia University
+6 more · Kaiser Permanente · Senders Pediatrics · University Hospitals Cleveland Medical Center · University of Pittsburgh · Valleywise Health · Washington University School of Medicine

Trials 3

today NCT06503900 · Ph 4 NCT06038617 · Ph 4 NCT06020118 · Ph 4
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 43 trials · 1 missed
Phase 4 NCT06503900 Sep 2024 → Aug 2025 — Duke University Completed No outcome recorded
Phase 4 NCT06038617 Oct 2023 → Apr 2025 — Duke University Completed No outcome recorded
Phase 4 NCT06020118 Sep 2023 → Mar 2024 COVID-19, influenza Duke University Completed Missed primary
Comparator or background therapy1 trial
Phase 2 NCT05672355 Comparator Aug 2023 → Jan 2029 B-cell chronic lymphocytic leukemia, COVID-19 City of Hope Medical Center Suspended Met primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as mRNA COVID-19 vaccine “approved mRNA COVID-19 vaccine (Moderna)” NCT06020118 ↗
3

NCT06038617 ↗

NCT05672355 ↗

NCT06503900 ↗
Modality Messenger RNA (mRNA) “SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccine administered as COVID-19 vaccine boosters.” NCT05672355 ↗
Route Intramuscular “Given IM” NCT05672355 ↗